The major vault protein (MVP), a new multidrug resistance associated protein, is frequently expressed in multiple myeloma

Leukemia and Lymphoma

Volumn 34, Issue 3-4, 1999, Pages 315-324

  Rimsza, Lisa M ^a,f   Campbell, K ^b   Dalton, W S ^c   Salmon, S ^b   Willcox, G ^d   Grogan, T M ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Tucson Med Center   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Ki 67; LRP; Major vault protein; Multidrug resistance; Multiple Myeloma; P gp

Indexed keywords

GLYCOPROTEIN P; KI 67 ANTIGEN; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; RIBONUCLEOPROTEIN;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL ANALYSIS;

EID: 0032840591     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909050956     Document Type: Article

References (34)

1. Kyle R: Diagnosis and management of multiple myeloma and related disorders. Pr Hematol 14: 257, 1986.
2. Durie B, Salmon S: The current status and future prospects of treatment of multiple myeloma. Clin Haematol 11: 181, 1982.
3. Dalton W, Grogan T, Rybski J, Scheper R, Richter L, Kailey J, Broxterman H, Pinedo H, Salmon S: Immunohistochemical detection and quatitation of P-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood 73: 747, 1989.
4. Salmon S, Grogan T, Miller T, Scheper R, Dalton W: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by p-glycoprotein staining. Journal of the National Cancer Institute 81: 696, 1989.
5. Grogan T, Spier C, Salmon S, Matzner M, Rybski J, Weinstein R, Scheper R, Dalton W: P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 81: 490, 1993.
6. Salmon S, Dalton W, Grogan T, Plezia P, Lehnert M, Roe D, Miller T: Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer. Blood 778: 44, 1991.
7. Sonneveld P, Durie B, Lokhorst H, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K: Modulation of multidrug-resistanc multiple myeloma by cyclosporin. The Lancet 340: 255, 1992.
8. Cole S, Bhardwaj G, Gerlach J, Mackie J, Grant C, Almquist K, Stewart A, Kurz E, Duncan A, Deeley R: Overexpression of a transporter gene in multidrug-resistant human lung cancer cell line. Science 258: 1650, 1992.
9. Flens M, Zaman G, van der Valk P, Izquierdo M, Schroeijers A, Scheffer G, van der Groep P, de Haas M, Meijer C, Scheper R: Tissue distribution of the multidrug resistance protein. American Journal of Pathology 148: 1237, 1996.
10. Grant C, Valdimarsson G, Hipfner D, Almquist K, Cole S, Deeley R: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Research 54: 357, 1994.
11. Scheper RJ, Broxterman HJ, Scheffer GL, Kaaijk P, Dalton WS, van Heijningen TH, van Kalken CK, Slovak ML, de Vries EG, van der Valk P, Meijer CJ, Pinedo HM: Overexpression of a Mr 100,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Research 53: 1475, 1993.
12. Izquierdo M, Scheffer G, Flens M, Giaccone G, Broxterman H, Meijer C, van der Valk P, Scheper R: Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumors. American Journal of Pathology 148: 877, 1996.
13. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1: 578, 1995.
14. Schuurhuis G, Broxterman H, Cervantes A, van Heijningen T, de Lange J, Baak J, Pinedo H, Lankelma J: Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. Journal of the National Cancer Institute 81: 1887, 1989.
15. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464, 1996.
16. Izquierdo MA, van der Zee AG, Vermorken JB, van der Valk P, Belien JA, Giaccone G, Scheffer GL, Flens MJ, Pinedo HM, Kenemans P, Meijer CJ, de Vries EG, Scheper RJ: Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. Journal of the National Cancer Institute 87: 1230, 1995.
17. den Boer ML, Pieters R, Kazemier KM, Rottier MMA, Zwaan CM, Kaspers GJL, Janka-Schaub G, Henze G, Creutzig U, Scheper RJ, Veerman AJP: Relationship between major vault protein/lung resistance protein, Multidrug resistance-associated protein, p-glycoprotein expression, and drug resistance in childhood leukemia. Blood 91: 2092, 1998.
18. Dalton W, Drurie B, Alberts D, Gerlach J, Cress A: Characterization of a new drug resistant human myeloma cell line that expresses p-glycoprotein. Cancer Research 46: 5125, 1986.
19. Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM: Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Research 51: 995, 1991.
20. Futscher B, Abbaszadegen M, Domann F, Dalton W: Analysis of MRP mRNA in mitoxantrone-selected, multidrug resistant human tumor cells. Biochem Pharmacol 47: 1601, 1994.
21. Abbaszadegan M, Foley N, Gleason-Guzman M, Dalton W: Resistance to the chemosensitizer verapamil in a multi-drug resistant (MDR) human multiple myeloma cell line. International Journal of Cancer 66: 506, 1996.
22. Grogan T, Dalton W, Rybski J, Spier C, Meltzer P, Richter L, Gleason M, Pindur J, Cline A, Scheper R, Tsuruo T, Salmon S: Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Laboratory Investigation 63: 815, 1990.
23. Grogan T, Rangel C, Rimsza L, et.al.: Kinetic-mode automated double labeled immunohistochemistry and in situ hybridization in diagnostic pathology, in Weinstein R (ed): Advances in Pathology and Laboratory Medicine, vol. 8, New York, Mosby, 1995.
24. Bhalla K, Hindenburg A, Taub R, Grant S: Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Research 45: 3657, 1985.
25. Wyler B, Shao Y, Schneider E, Cianfriglia M, Scheper RJ, Frey BM, Gieseler F, Schmid L, Twentyman P, Lehnert M: Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. British Journal of Haematology 97: 65, 1996.
26. Abbaszadegan M, Futscher B, Klimecki W, List A, Dalton W: Analysis of multidrug resistance-associated proteim (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Research 54: 4676, 1994.
27. Izquierdo M, Shoemaker R, Flens M, Scheffer G, Wu L, Prather T, Scheper R: Overlapping phenotypes of multidrug resistance among panels of human cancer cell lines. International Journal of Cancer 65: 230, 1996.
28. Wu L, Smythe A, Stinson S, al. e: Multidrug resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Research 52: 3029, 1992.
29. Izquierdo M, Scheffer G, Flens M, Shoemaker R, Rome L, Scheper R: Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 19: 191, 1996.
30. Izquierdo M, Neefjes J, Mathari A, Flens M, Scheffer G, Scheper R: Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines. British Journal of Cancer 74: 1961, 1996.
31. Goasguen J, Lamy T, Bergeron C, Ly Sunaram B, Mordelet E, Gorre G, Dossot J, Le Gall E, Grosbois B, Le Prise P, Fauchet R: Multifactorial drug-resistance phenomenon in acute leukemias: impact of P170-MDR1, LRP56 protein, glutathione-transferases and metallothionein systems on clinical outcome. Leukemia and Lymphoma 23: 567, 1996.
32. Danks M, Schmidt C, Cirtain M, Suttle D, Beck W: Altered catalytic activity of an DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry 27: 8861, 1988.
33. Raaijmakers HGP, Izquierdo MA, Lokhorst HM, de Leeuw C, Belien JAM, Bloem AC, Dekker AW, Scheper RJ, Sonneveld P: Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 91: 1029, 1998.
34. San Miguel JF, Garcia-Sanz r, Gonzalez M, Moro MJ, Hernandez JM, Ortega F, Borrego D, Carnero M, Casanova F, Jimenez R, Portero JA, Orfao A: A new staging system for multiple myeloma based on the number of S-phase plasma cells. Blood 85: 448, 1995.